Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   

bladder calculi1 - kidney blood pressure1 - fecal incontinence3 - reiter's syndrome2 - xtandi1 - prostate cancer imaging1 - catheter malfunction1 - statins1 - abbott diagnostics1 - male pattern baldness1 - vitamin k1 - arteriovenous fistula4 - resistant bacteria1 - ckd progression1 - rare kidney disease1 - aurora a kinase1 - testosterone therapy1 - nephrosis1 - early kidney disease1 - gonadal vessels1 - outlet obstruction6 - blood vessels3 - ips cells1 - pharmaceutical science1 - urinary bladder1 - amgen1 - running1 - bulbocavernosus reflex1 - intravenous fluids1 - yeshiva university1 -